logo

Improving CAR-T cell therapies through AAV-mediated genetic engineering

Sector: Hospital • Location: Sweden

Source: EU Funding & Tenders Portal

Project
Ongoing

T cells expressing chimeric antigen receptors (CAR) have transformed cell therapies against some hematological cancers. As a postdoc, I evolved a synthetic adeno-associated virus (AAV) with tropism against murine T cells, providing a unique tool to study gene targeted T cells in immunocompetent cancer models. In this proposal, capitalizing on my break-through, I will develop novel strategies to ge

Project Information FAQ

Project Information

3 Q
The project “Improving CAR-T cell therapies through AAV-mediated genetic engineering” is an infrastructure initiative in the Hospital sector, located in Sweden. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ongoing

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

T cells expressing chimeric antigen receptors (CAR) have transformed cell therapies against some hematological cancers. As a postdoc, I evolved a synthetic adeno-associated virus (AAV) with tropism against murine T cells, providing a unique tool to study gene targeted T cells in immunocompetent cancer models. In this proposal, capitalizing on my break-through, I will develop novel strategies to generate gene targeted CAR-T cells in vivo, optimizing AAV delivery in immunocompetent mouse models and combining these methods with technologies for Cas9 delivery for T cell-specific gene editing. The ultimate goal of my proposal is to develop methods that can be translated to clinical trials in humans. Therefore, I will establish a humanized mouse model that allows for targeting of human T cells in vivo, in which key findings from this research project will be translated for proof-of-concept experiments. As the first ever study of gene targeted T cells in vivo, this ground-breaking research will provide in-depth profiling of in vivo engineered CAR-T cells and their therapeutic potential. This study is a necessary first step forwards toward accessible and affordable in vivo generated CAR-T cell therapies in humans. Furthermore, to extend the use of CAR-T cells against solid tumor, I have developed an AAV-based platform to perform pooled knock-in T cell screens in immunocompetent solid tumor mouse models. For this research proposal, I have designed a library of synthetic costimulatory receptors to be expressed with a CAR at the Trac locus to improve T cell fitness and persistence. By combining advanced T cell engineering with analysis on single-cell level, these pioneering experiments will answer crucial questions for T cell therapies and tumor biology. To succeed with my ambitious and unconventional proposal, I plan to join the Department of Medicine, Huddinge, at the Karolinska Institute. Building a collaborative team in an excellent translational research environment.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data